S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Wall Street rises to more records to close out its latest winning month
Delta Airline’s Put Option Activity Isn’t Bad News
Disney Stock Catches 3 Upgrades In a Single Week
3 Value Stocks Too Small For Buffett’s Portfolio
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:LIXT

Lixte Biotechnology (LIXT) Stock Price, News & Analysis

$3.38
-0.14 (-3.98%)
(As of 03/28/2024 ET)
Today's Range
$3.19
$3.79
50-Day Range
$1.73
$3.52
52-Week Range
$1.58
$9.60
Volume
879,579 shs
Average Volume
560,680 shs
Market Capitalization
$7.61 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
LIXT stock logo

About Lixte Biotechnology Stock (NASDAQ:LIXT)

Lixte Biotechnology Holdings, Inc. operates as a drug discovery company that uses biomarker technology to design novel compounds for serious common diseases. The company primarily focuses on inhibitors of protein phosphatases that are used alone and in combination with cytotoxic agents and/or x-ray and immune checkpoint blockers; and encompasses two major categories of compounds at various stages of pre-clinical and clinical development. It develops two series of pharmacologically active drugs, which include the LB-100 series that consists of novel structures for the treatment of cancers, and vascular and metabolic diseases; and LB-200 series to treat chronic hereditary diseases, such as Gaucher's disease, as well as cancer and neurodegenerative diseases. Lixte Biotechnology Holdings, Inc. has a clinical trial research agreement with the Moffitt Cancer Center and Research Institute Hospital Inc.; collaboration agreement for an investigator-initiated clinical trial with the Spanish Sarcoma Group, as well as Netherlands Cancer Institute and Oncode Institute. Lixte Biotechnology Holdings, Inc. was founded in 2005 and is based in Pasadena, California.

LIXT Stock Price History

LIXT Stock News Headlines

Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
Lixte Biotechnology Holdings Inc LIXT
Lixte Biotechnology Holdings Inc. Wt
See More Headlines
Receive LIXT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Lixte Biotechnology and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/04/2016
Today
3/28/2024
Next Earnings (Estimated)
5/08/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:LIXT
Employees
3
Year Founded
N/A

Profitability

Net Income
$-5,090,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
$0.22 per share

Miscellaneous

Free Float
1,900,000
Market Cap
$7.92 million
Optionable
Not Optionable
Beta
-0.31
12 Stocks Corporate Insiders are Abandoning Cover

If a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?

Get This Free Report

Key Executives

  • Mr. Bastiaan van der Baan M.Sc. (Age 52)
    President, CEO & Chairman of the Board of Directors
    Comp: $11.87k
  • Mr. Robert Neal Weingarten (Age 72)
    VP & CFO
    Comp: $175k
  • Mr. Eric J. Forman J.D. (Age 45)
    VP & COO
    Comp: $178.82k
  • Dr. James S. Miser M.D. (Age 77)
    Chief Medical Officer
    Comp: $175k

LIXT Stock Analysis - Frequently Asked Questions

How have LIXT shares performed in 2024?

Lixte Biotechnology's stock was trading at $2.35 at the beginning of 2024. Since then, LIXT shares have increased by 43.8% and is now trading at $3.38.
View the best growth stocks for 2024 here
.

Are investors shorting Lixte Biotechnology?

Lixte Biotechnology saw a decline in short interest in the month of March. As of March 15th, there was short interest totaling 19,600 shares, a decline of 62.3% from the February 29th total of 52,000 shares. Based on an average trading volume of 36,800 shares, the days-to-cover ratio is currently 0.5 days. Currently, 1.1% of the company's stock are short sold.
View Lixte Biotechnology's Short Interest
.

When is Lixte Biotechnology's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, May 8th 2024.
View our LIXT earnings forecast
.

How were Lixte Biotechnology's earnings last quarter?

Lixte Biotechnology Holdings, Inc. (NASDAQ:LIXT) posted its quarterly earnings results on Friday, November, 4th. The company reported ($0.10) EPS for the quarter.

When did Lixte Biotechnology's stock split?

Lixte Biotechnology's stock reverse split on the morning of Monday, June 5th 2023. The 1-10 reverse split was announced on Monday, June 5th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, June 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.

When did Lixte Biotechnology IPO?

Lixte Biotechnology (LIXT) raised $7 million in an initial public offering (IPO) on Wednesday, November 25th 2020. The company issued 1,500,000 shares at a price of $4.75 per share. WestPark Capital and WallachBeth Capital served as the underwriters for the IPO.

How do I buy shares of Lixte Biotechnology?

Shares of LIXT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:LIXT) was last updated on 3/28/2024 by MarketBeat.com Staff

From Our Partners